[HTML][HTML] A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
…, JM Kremer, AD Bankhurst, KJ Bulpitt… - … England Journal of …, 1999 - Mass Medical Soc
Background Patients treated with methotrexate for rheumatoid arthritis often improve but
continue to have active disease. This study was undertaken to determine whether the addition …
continue to have active disease. This study was undertaken to determine whether the addition …
Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial
…, EA Tindall, RM Fleischmann, KJ Bulpitt… - Annals of internal …, 1999 - acpjournals.org
Background: In a phase II study, etanercept (recombinant human tumor necrosis factor
receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in …
receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in …
Studies of sequence heterogeneity of mitochondrial DNA from rat and mouse tissues: evidence for an increased frequency of deletions/additions with aging
L Pikó, AJ Hougham, KJ Bulpitt - Mechanisms of ageing and development, 1988 - Elsevier
… Pik6, KJ Bulpitt and R. Meyer, Structural and replicative forms of mitochondrial DNA in …
14 KJ Bulpitt and L. Pik6, Variation in the frequency of complex forms of mitochondrial DNA in …
14 KJ Bulpitt and L. Pik6, Variation in the frequency of complex forms of mitochondrial DNA in …
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.
…, SW Baumgartner, EA Tindall, K Bulpitt… - The Journal of …, 2001 - jrheum.org
OBJECTIVE: Patients with rheumatoid arthritis (RA) treated with etanercept (Enbrel) in controlled
studies of 3 to 6 months' duration had rapid and sustained improvement of their disease…
studies of 3 to 6 months' duration had rapid and sustained improvement of their disease…
Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine …
Objective To test the hypothesis that an artificial peptide, based on an algorithm describing
T cell stimulatory sequences from the V H regions of murine IgG antibodies to DNA, is an …
T cell stimulatory sequences from the V H regions of murine IgG antibodies to DNA, is an …
Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and …
…, GS Alarcon, R Joks, VD Steen, K Bulpitt… - The Journal of …, 1999 - europepmc.org
Objective (1) To review the diagnoses after 10 years in patients who were identified within
12 months of the onset of well established and undifferentiated connective tissue diseases (…
12 months of the onset of well established and undifferentiated connective tissue diseases (…
Campath‐1h, a humanized monoclonal antibody, in refractory rheumatoid arthritis
ME Weinblatt, PJ Maddison, KJ Bulpitt… - … : Official Journal of …, 1995 - Wiley Online Library
Objective. To evaluate the biologic response, tolerability, and potential clinical effect of a
humanized antilymphocyte monoclonal antibody, CAMPATH‐1H, in patients with rheumatoid …
humanized antilymphocyte monoclonal antibody, CAMPATH‐1H, in patients with rheumatoid …
Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo‐controlled trials
…, J Goldin, M Roth, D Furst, K Bulpitt… - Arthritis care & …, 2018 - Wiley Online Library
Objective To assess the efficacy of mycophenolate mofetil ( MMF ) and cyclophosphamide (
CYC ) on modified Rodnan skin score ( MRSS ) in participants enrolled in the Scleroderma …
CYC ) on modified Rodnan skin score ( MRSS ) in participants enrolled in the Scleroderma …
Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations
…, ME Weinblatt, AD Bankhurst, KJ Bulpitt… - … : Official Journal of …, 2003 - Wiley Online Library
Objective To observe the long‐term safety and efficacy of combination therapy with etanercept
and methotrexate in patients with rheumatoid arthritis (RA), and to determine whether the …
and methotrexate in patients with rheumatoid arthritis (RA), and to determine whether the …
CAMPATH-1H in rheumatoid arthritis—an intravenous dose-ranging study
JD Isaacs, VK Manna, N Rapson, KJ Bulpitt… - …, 1996 - academic.oup.com
Forty-one patients with active and refractory rheumatoid arthritis (RA) received a total of 100,
250 or 400 mg of CAMPATH-1H (CAMPATH is a trademark of Glaxo-Wellcome group …
250 or 400 mg of CAMPATH-1H (CAMPATH is a trademark of Glaxo-Wellcome group …